long intergenic non-protein coding RNA 2360Genealiases: []
Q-omics provides the consensus-scored LINC02360 profile across patient tissues and cancer cell-line models. LINC02360 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC02360 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, LINC02360 RNA expression shows 8,119 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight MESO, KIRC, and KIRP as cancer lineages where LINC02360 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02360 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02360 survival associations across molecular data types. LINC02360 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02360 RNA expression–survival associations across cancer types. High LINC02360 expression shows unfavorable associations in DLBC, BRCA, KIRC and KICH, but favorable associations in MESO and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC02360 RNA expression.
This table summarizes LINC02360 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02360. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02360 shows lower tumor expression in KIRC, COAD, KICH, THCA, KIRP and UCEC. The KIRC box plot shows higher LINC02360 RNA expression in normal versus tumor tissue (log2 FC = −1.061, t-test p < 0.001).
This table shows molecular features associated with LINC02360 in patient tissues and cancer cell lines. In patient samples, LINC02360 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
